BofA analysts upgraded shares of Gilead Sciences (NASDAQ:GILD) to Buy from Neutral, with a price target of $95, up from $88 per share, in a note to clients on Friday. The analysts...
Gilead Sciences (NASDAQ:GILD) announced Monday that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on the initiation of new patients in U.S. studies...
(Reuters) -Gilead Sciences (NASDAQ:GILD) said on Monday the U.S. health regulator placed a clinical hold on studies of its blood cancer drug, just a month after the company...
By Michael Erman (Reuters) -Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment...
Investing.com - Gilead (NASDAQ: GILD) reported second quarter EPS of $1.34, $0.31 worse than the analyst estimate of $1.65. Revenue for the quarter came in at $6.6B versus the...
By Sruthi Shankar and Medha Singh (Reuters) -A "special rebalance" of the Nasdaq 100 index will take place later this month as exchange operator Nasdaq looks to reduce the...
High dividend-paying stocks are down 7% this year versus gains of 9% and 26% for the S&P 500 and Nasdaq, respectively. Now, it is time for investors to prepare for them to rebound,...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) in...